S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SION · Sionna Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Sionna Therapeutics Inc (SION)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$3.87
-0.27
(-6.52%)
● At close: October 21 at 4:00:00 PM EDT
$3.95
+0.08
(+2.07%)
Overnight:
2:25:00 AM EDT
DAY'S RANGE
$3.87
$3.86
$4.26
52-WEEK RANGE
$3.87
$3.77
$54.97
What's happening
- SION is down 6.52% today, trading at $3.87. — Live quote
- It's trading within 3% of its 52-week low ($3.77). (Finnhub fundamentals)
- Volume today (76,095) is well below its 3-month average of 1,749,350. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.66 actual vs. $-0.66 estimated (+0.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 11
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SION
-89.91%
vs S&P 500
-102.69%
1-YEAR RETURN
SION
-87.11%
vs S&P 500
-101.67%
6-MONTH RETURN
SION
-90.83%
3-MONTH RETURN
SION
-91.21%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.66
Est. $-0.66
BEAT +0.4%
2026-04-26 (Q1 2026)
$-0.60
Est. $-0.52
MISS -14.4%
2026-01-26 (Q4 2025)
$-0.46
Est. $-0.55
BEAT +16.3%
2025-10-26 (Q3 2025)
$-0.46
Est. $-0.49
BEAT +6.9%
Valuation Measures & Ratios
Enterprise Value4$124.3M
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)—
Price / Book77.47
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-32.94%
Return on Assets (ROA9)-31.08%
Avg Volume (3M)1,749,350
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.99B | $1.79B | $1.30B | $771.4M | $280.2M |
| P/E | -20.95 | -21.95 | -16.17 | -11.25 | -4.50 |
| Price/Book | 7.49 | 6.21 | 4.04 | 2.29 | 0.80 |
| ROE | -35.75% | -28.32% | -24.95% | -20.37% | -17.72% |
| ROA | -33.54% | -26.75% | -23.66% | -19.47% | -16.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,797,732
Change from Prior Settlement-4.25%
% of Float—
Days to Cover (Short Ratio)2.30
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -87.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SION
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$32.5M | -$29.6M | -$23.8M | -$21.9M | -$19.7M | -$28.0M | -$11.3M | -$13.1M |
| Net income | -$29.9M | -$26.8M | -$20.3M | -$18.1M | -$16.5M | -$25.4M | -$8.6M | -$11.8M |
| EPS (diluted) | $-0.66 | $-0.60 | $-0.46 | $-0.41 | $-0.62 | $-5.67 | $-2710.00 | $-3840.00 |
| EPS (basic) | $-0.66 | $-0.60 | $-0.46 | $-0.41 | $-0.62 | $-5.67 | $-2710.00 | $-3840.00 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $283.2M | $305.0M | $326.0M | $339.3M | $352.0M | $369.7M | $185.8M | — |
| Total liabilities | $17.5M | $16.8M | $19.1M | $17.6M | $15.6M | $17.9M | $19.1M | — |
| Stockholders' equity | $265.8M | $288.2M | $306.8M | $321.7M | $336.4M | $351.8M | -$163.7M | -$148.5M |
| Total current assets | $216.1M | $221.0M | $241.4M | $252.3M | $266.7M | $273.7M | $151.0M | — |
| Total current liabilities | $10.8M | $9.8M | $11.7M | $9.9M | $7.5M | $9.5M | $10.4M | — |
| Cash & equivalents | $63.3M | $63.3M | $58.5M | $50.8M | $41.0M | $82.7M | $37.8M | $35.7M |
| Property, plant & equipment | $1.9M | $2.1M | $2.2M | $2.1M | $2.2M | $2.4M | $2.5M | — |
| Other non-current assets | $594.0K | $585.0K | $0 | $0 | $0 | $0 | $3.0M | — |
| Accrued liabilities | $8.9M | $6.3M | $9.7M | $6.9M | $5.5M | $3.4M | $8.2M | — |
| Other current liabilities | $7.0K | $17.0K | $6.0K | $224.0K | — | — | $0 | — |
| Common stock & paid-in capital | $45.0K | $45.0K | $45.0K | $44.0K | $44.0K | $44.0K | $5.0K | — |
| Retained earnings | -$313.0M | -$283.1M | -$256.4M | -$235.9M | -$215.6M | -$197.6M | -$181.1M | — |
| Accumulated other comprehensive income (loss) | -$448.0K | -$84.0K | $540.0K | $420.0K | $183.0K | $301.0K | $368.0K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.2M | -$21.8M | -$16.6M | -$15.2M | -$18.2M | -$16.3M | -$11.8M | -$17.7M |
| Investing cash flow | $21.5M | $24.8M | $22.6M | $23.1M | -$23.2M | -$141.2M | $15.2M | $10.4M |
| Financing cash flow | $749.0K | $1.9M | $1.7M | $2.0M | -$312.0K | $202.4M | -$1.4M | -$996.0K |
| Free cash flow | -$22.2M | -$21.8M | -$16.8M | -$15.3M | -$18.2M | -$16.4M | -$11.8M | -$17.7M |
| Capital expenditures | $0 | $0 | $204.0K | $87.0K | $0 | $86.0K | $27.0K | $0 |
| Share-based compensation | $6.8M | $6.6M | $3.8M | $3.3M | $2.8M | $2.1M | $1.1M | $1.0M |
| Change in accounts payable | -$1.5M | $1.2M | -$712.0K | $567.0K | -$3.8M | $3.6M | $1.1M | -$1.8M |
| Purchases of investments | $33.0M | $25.3M | $42.9M | $54.1M | $56.4M | $171.6M | $7.2M | $23.1M |
| Sales/maturities of investments | $54.5M | $50.1M | $65.7M | $77.3M | $33.2M | $30.5M | $22.5M | $33.5M |
Income statement
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Operating income | -$89.0M | -$70.6M |
| Net income | -$75.3M | -$61.7M |
| EPS (diluted) | $-1.88 | $-15.99 |
| EPS (basic) | $-1.88 | $-15.99 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Total assets | $326.0M | $185.8M | — |
| Total liabilities | $19.1M | $19.1M | — |
| Stockholders' equity | $306.8M | -$163.7M | -$114.9M |
| Total current assets | $241.4M | $151.0M | — |
| Total current liabilities | $11.7M | $10.4M | — |
| Cash & equivalents | $58.5M | $37.8M | — |
| Property, plant & equipment | $2.2M | $2.5M | — |
| Other non-current assets | $0 | $3.0M | — |
| Accrued liabilities | $9.7M | $8.2M | — |
| Other current liabilities | $6.0K | $0 | — |
| Common stock & paid-in capital | $45.0K | $5.0K | — |
| Retained earnings | -$256.4M | -$181.1M | — |
| Accumulated other comprehensive income (loss) | $540.0K | $368.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Operating cash flow | -$66.3M | -$52.8M |
| Investing cash flow | -$118.7M | -$126.9M |
| Financing cash flow | $205.7M | $179.0M |
| Free cash flow | -$66.7M | -$52.8M |
| Capital expenditures | $377.0K | $27.0K |
| Share-based compensation | $12.1M | $3.7M |
| Change in accounts payable | -$417.0K | $467.0K |
| Purchases of investments | $325.0M | $182.8M |
| Sales/maturities of investments | $206.7M | $56.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SION as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers97.1%
Shares Outstanding45,148,971
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9,905,045 | $435.7M | 21.94% | +0.0% | 2026-08-14 |
| TPG GP A, LLC | 6,494,962 | $285.7M | 14.39% | +0.0% | 2026-08-14 |
| VIKING GLOBAL INVESTORS LP | 3,195,181 | $140.6M | 7.08% | +0.0% | 2026-08-14 |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | $131.8M | 6.63% | +0.0% | 2026-08-13 |
| ORBIMED ADVISORS LLC | 2,555,877 | $112.4M | 5.66% | -27.6% | 2026-08-14 |
| Enavate Sciences GP, LLC | 2,478,030 | $109.0M | 5.49% | +0.0% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,600,000 | $70.4M | 3.54% | +966.7% | 2026-08-14 |
| Jpmorgan Chase & Co | 1,490,508 | $64.1M | 3.30% | +1.7% | 2026-08-12 |
| BlackRock, Inc. | 1,474,769 | $64.9M | 3.27% | +13.8% | 2026-08-07 |
| JENNISON ASSOCIATES LLC | 1,172,133 | $51.6M | 2.60% | -19.2% | 2026-08-03 |
| CITADEL ADVISORS LLC | 1,147,636 | $50.5M | 2.54% | -1.7% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,132,001 | $49.8M | 2.51% | +10.0% | 2026-06-30 |
| State Street Corp | 1,021,534 | $44.9M | 2.26% | +35.1% | 2026-08-07 |
| PERCEPTIVE ADVISORS LLC | 905,000 | $39.8M | 2.00% | +37.4% | 2026-08-14 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 680,916 | $30.0M | 1.51% | -29.8% | 2026-08-14 |
| Siren, L.L.C. | 610,515 | $26.9M | 1.35% | +103.5% | 2026-08-13 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 478,016 | $21.0K | 1.06% | -36.8% | 2026-08-14 |
| EVENTIDE ASSET MANAGEMENT, LLC | 474,981 | $20.9M | 1.05% | -26.4% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 457,145 | $20.1M | 1.01% | +17.3% | 2026-08-12 |
| BAKER BROS. ADVISORS LP | 400,000 | $17.6M | 0.89% | +0.0% | 2026-08-14 |
| Casdin Capital, LLC | 400,000 | $17.6M | 0.89% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 388,810 | $17.1M | 0.86% | +47.7% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 385,447 | $17.0M | 0.85% | +403.0% | 2026-08-14 |
| Franklin Templeton Inc | 290,113 | $12.8M | 0.64% | +65.3% | 2026-08-04 |
| Aberdeen Group plc | 284,138 | $12.5M | 0.63% | -49.6% | 2026-07-31 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-17 to 2026-09-17
Recent transactions
- Insiders have net sold 4,448,691 shares over the last 182 days, across 0 purchases and 15 sales.
- Most recent: RA CAPITAL MANAGEMENT, L.P. (Reporting person) — Open market sale of 3,415,011 shares on 2026-09-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)4,448,691 sh(15 txns)
Net Shares-4,448,691
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 2026-09-17 | 3,415,011 |
| Ridloff Elena | CFO and CBO | Grant / award | 2026-09-17 | 47,269 |
| McKee Charlotte | CMO and Head of R&D | Grant / award | 2026-09-17 | 50,000 |
| Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | Grant / award | 2026-09-17 | 28,133 |
| Cloonan Michael | President & CEO | Grant / award | 2026-09-17 | 109,025 |
| Thompson Peter A. | Director | Open market sale | 2026-07-07 | 85,918 |
| ORBIMED ADVISORS LLC | Director | Open market sale | 2026-07-07 | 85,918 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 3,415,011 | $6.32 |
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 33,800 | $7.46 |
| 2026-09-17 | Ridloff Elena | CFO and CBO | Grant / award | 47,269 | $0.00 |
| 2026-09-17 | Ridloff Elena | CFO and CBO | Grant / award | 47,268 | $0.00 |
| 2026-09-17 | McKee Charlotte | CMO and Head of R&D | Grant / award | 50,000 | $0.00 |
| 2026-09-17 | McKee Charlotte | CMO and Head of R&D | Grant / award | 50,000 | $0.00 |
| 2026-09-17 | Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | Grant / award | 28,133 | $0.00 |
| 2026-09-17 | Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | Grant / award | 28,132 | $0.00 |
| 2026-09-17 | Cloonan Michael | President & CEO | Grant / award | 109,025 | $0.00 |
| 2026-09-17 | Cloonan Michael | President & CEO | Grant / award | 109,025 | $0.00 |
| 2026-07-07 | Thompson Peter A. | Director | Open market sale | 85,918 | $44.86 |
| 2026-07-07 | ORBIMED ADVISORS LLC | Director | Open market sale | 85,918 | $44.86 |
| 2026-07-06 | Fitzpatrick Jennifer | Chief Legal Officer | Option exercise | 10,250 | $6.11 |
| 2026-07-06 | Fitzpatrick Jennifer | Chief Legal Officer | Open market sale | 10,250 | $43.60 |
| 2026-06-30 | Thompson Peter A. | Director | Open market sale | 115,844 | $45.50 |
| 2026-06-30 | ORBIMED ADVISORS LLC | Director | Open market sale | 115,844 | $45.50 |
| 2026-05-27 | Thompson Peter A. | Director | Open market sale | 101 | $44.49 |
| 2026-05-27 | ORBIMED ADVISORS LLC | Director | Open market sale | 101 | $44.49 |
| 2026-05-11 | Thompson Peter A. | Director | Open market sale | 184,639 | $46.22 |
| 2026-05-11 | ORBIMED ADVISORS LLC | Director | Open market sale | 184,639 | $46.22 |
| 2026-05-08 | Thompson Peter A. | Director | Open market sale | 59,767 | $44.58 |
| 2026-05-08 | ORBIMED ADVISORS LLC | Director | Open market sale | 59,767 | $44.58 |
| 2026-05-07 | Thompson Peter A. | Director | Open market sale | 48,546 | $44.61 |
| 2026-05-07 | ORBIMED ADVISORS LLC | Director | Open market sale | 48,546 | $44.61 |
| 2026-04-18 | Thompson Peter A. | Director | Open market sale | 2,948 | $44.52 |
| 2026-04-18 | ORBIMED ADVISORS LLC | Director | Open market sale | 2,948 | $44.52 |
| 2026-04-17 | Thompson Peter A. | Director | Open market sale | 52,397 | $44.68 |
| 2026-04-17 | ORBIMED ADVISORS LLC | Director | Open market sale | 52,397 | $44.68 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-21 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-09 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-09 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-06 | View on SEC.gov → |
Recent news
Headlines about SION (Sionna Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
CM Fadnavis to open three key Mumbai bridges; check how Sion, Vidyavihar and GMLR will help - Mid-Day
Mid-Day · 2026-10-22 -
Big Boost For Mumbai Infra: Sion, Vidyavihar And Goregaon Flyovers To Open On Thursday | Check Photos
NDTV Profit · 2026-10-22 -
Mumbai gets 3 key flyovers: Sion, Vidyavihar, Goregaon-Mulund Link Road to open on Oct 22
The Times of India · 2026-10-21 -
SION Jan 2027 30.000 call (SION270115C00030000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Mumbai's Sion Bridge Ready But Shut: Locals Bring Crane To Remove Barricades Over VIP Inauguration Delay
NDTV Profit · 2026-10-21 -
Sion's seven-goal thriller ends in narrow defeat
strabaneweekly.co.uk · 2026-10-19 -
SION261016P00020000 interactive stock chart | SION Oct 2026 20.000 put stock
Yahoo Finance Australia · 2026-10-18 -
Mumbai Bridge Update: When Will Sion, Vidyavihar Bridges And Goregaon Connector Open?
NDTV Profit · 2026-10-18
No headlines in this category right now — try “All”.